A randomised controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate versus ciclosporin in the treatment of severe atopic eczema in children: The TREatment of severe Atopic eczema Trial (TREAT).

@article{Irvine2018ARC,
  title={A randomised controlled trial protocol assessing the effectiveness, safety and cost-effectiveness of methotrexate versus ciclosporin in the treatment of severe atopic eczema in children: The TREatment of severe Atopic eczema Trial (TREAT).},
  author={Alan D Irvine and Ashley Jones and Paula E Beattie and Susannah E Baron and Fiona Browne and F Ashoor and Linda O'Neill and Anna Rosala-Hallas and Tracey H Sach and Catherine Spowart and Leonie S Taams and Charlotte Walker and Mandy Wan and Nicholas J. A. Webb and Paula R Williamson and C Flohr},
  journal={The British journal of dermatology},
  year={2018}
}
BACKGROUND Oral systemic immuno-modulatory medication is regularly used off-licence in children with severe atopic eczema. However, there is no firm evidence regarding the effectiveness, safety, cost-effectiveness and impact on quality of life from an adequately powered randomised controlled trial (RCT) using systemic medication in children. PATIENTS/METHODS Multi-centre, parallel group, assessor-blind, pragmatic RCT of 36 week duration with a 24 week follow-up period. 102 children aged 2-16… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.
1 Citations
0 References
Similar Papers

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…